Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.59
ISIS's Cash to Debt is ranked higher than
58% of the 1428 Companies
in the Global Biotechnology industry.

( Industry Median: 39.38 vs. ISIS: 1.59 )
ISIS' s 10-Year Cash to Debt Range
Min: 0.34   Max: 4.79
Current: 1.59

0.34
4.79
Equity to Asset 0.27
ISIS's Equity to Asset is ranked higher than
52% of the 1094 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ISIS: 0.27 )
ISIS' s 10-Year Equity to Asset Range
Min: -0.35   Max: 0.76
Current: 0.27

-0.35
0.76
F-Score: 3
Z-Score: 6.33
M-Score: -3.20
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -22.29
ISIS's Operating margin (%) is ranked higher than
78% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -96.70 vs. ISIS: -22.29 )
ISIS' s 10-Year Operating margin (%) Range
Min: -438.91   Max: -12.18
Current: -22.29

-438.91
-12.18
Net-margin (%) -18.20
ISIS's Net-margin (%) is ranked higher than
78% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. ISIS: -18.20 )
ISIS' s 10-Year Net-margin (%) Range
Min: -334.33   Max: 127.52
Current: -18.2

-334.33
127.52
ROE (%) -11.32
ISIS's ROE (%) is ranked higher than
80% of the 1311 Companies
in the Global Biotechnology industry.

( Industry Median: -30.34 vs. ISIS: -11.32 )
ISIS' s 10-Year ROE (%) Range
Min: -280.13   Max: 86.43
Current: -11.32

-280.13
86.43
ROA (%) -4.59
ISIS's ROA (%) is ranked higher than
82% of the 1436 Companies
in the Global Biotechnology industry.

( Industry Median: -25.14 vs. ISIS: -4.59 )
ISIS' s 10-Year ROA (%) Range
Min: -59.44   Max: 25.19
Current: -4.59

-59.44
25.19
ROC (Joel Greenblatt) (%) -52.50
ISIS's ROC (Joel Greenblatt) (%) is ranked higher than
80% of the 1397 Companies
in the Global Biotechnology industry.

( Industry Median: -359.85 vs. ISIS: -52.50 )
ISIS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -800.86   Max: -54.5
Current: -52.5

-800.86
-54.5
Revenue Growth (3Y)(%) 22.50
ISIS's Revenue Growth (3Y)(%) is ranked higher than
89% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. ISIS: 22.50 )
ISIS' s 10-Year Revenue Growth (3Y)(%) Range
Min: -39.4   Max: 83.7
Current: 22.5

-39.4
83.7
EBITDA Growth (3Y)(%) -30.30
ISIS's EBITDA Growth (3Y)(%) is ranked higher than
59% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. ISIS: -30.30 )
ISIS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -49.6   Max: 61.3
Current: -30.3

-49.6
61.3
EPS Growth (3Y)(%) -27.00
ISIS's EPS Growth (3Y)(%) is ranked higher than
62% of the 803 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. ISIS: -27.00 )
ISIS' s 10-Year EPS Growth (3Y)(%) Range
Min: -71.2   Max: 117.8
Current: -27

-71.2
117.8
» ISIS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ISIS Guru Trades in Q1 2014

George Soros 5,539 sh (New)
Ron Baron 45,251 sh (New)
Steven Cohen 74,106 sh (+768.67%)
Murray Stahl 17,000 sh (unchged)
Jim Simons 136,914 sh (-58.02%)
» More
Q2 2014

ISIS Guru Trades in Q2 2014

Murray Stahl 17,000 sh (unchged)
Ron Baron Sold Out
Jim Simons Sold Out
George Soros Sold Out
» More
Q3 2014

ISIS Guru Trades in Q3 2014

Murray Stahl 17,000 sh (unchged)
» More
Q4 2014

ISIS Guru Trades in Q4 2014

Paul Tudor Jones 6,473 sh (New)
Joel Greenblatt 8,745 sh (New)
Murray Stahl 17,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ISIS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 28.60
ISIS's P/B is ranked lower than
61% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. ISIS: 28.60 )
ISIS' s 10-Year P/B Range
Min: 3   Max: 1710
Current: 28.6

3
1710
P/S 34.10
ISIS's P/S is ranked higher than
54% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 36.81 vs. ISIS: 34.10 )
ISIS' s 10-Year P/S Range
Min: 4.33   Max: 84.47
Current: 34.1

4.33
84.47
POCF 1327.40
ISIS's POCF is ranked higher than
87% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ISIS: 1327.40 )
ISIS' s 10-Year POCF Range
Min: 3.54   Max: 1473
Current: 1327.4

3.54
1473
EV-to-EBIT -159.83
ISIS's EV-to-EBIT is ranked higher than
76% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ISIS: -159.83 )
ISIS' s 10-Year EV-to-EBIT Range
Min: -198.4   Max: 596.9
Current: -159.83

-198.4
596.9
Current Ratio 7.25
ISIS's Current Ratio is ranked higher than
82% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. ISIS: 7.25 )
ISIS' s 10-Year Current Ratio Range
Min: 2.81   Max: 9.1
Current: 7.25

2.81
9.1
Quick Ratio 7.20
ISIS's Quick Ratio is ranked higher than
83% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. ISIS: 7.20 )
ISIS' s 10-Year Quick Ratio Range
Min: 2.81   Max: 9.1
Current: 7.2

2.81
9.1
Days Sales Outstanding 6.65
ISIS's Days Sales Outstanding is ranked higher than
97% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 134.01 vs. ISIS: 6.65 )
ISIS' s 10-Year Days Sales Outstanding Range
Min: 1.87   Max: 86.04
Current: 6.65

1.87
86.04

Valuation & Return

vs
industry
vs
history
Price/Net Cash 238.50
ISIS's Price/Net Cash is ranked higher than
54% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 103.40 vs. ISIS: 238.50 )
ISIS' s 10-Year Price/Net Cash Range
Min: 5.27   Max: 237.46
Current: 238.5

5.27
237.46
Price/Net Current Asset Value 200.10
ISIS's Price/Net Current Asset Value is ranked higher than
51% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 42.30 vs. ISIS: 200.10 )
ISIS' s 10-Year Price/Net Current Asset Value Range
Min: 4.77   Max: 118.17
Current: 200.1

4.77
118.17
Price/Tangible Book 30.90
ISIS's Price/Tangible Book is ranked lower than
60% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 10.90 vs. ISIS: 30.90 )
ISIS' s 10-Year Price/Tangible Book Range
Min: 2.82   Max: 216.67
Current: 30.9

2.82
216.67
Price/Median PS Value 2.70
ISIS's Price/Median PS Value is ranked higher than
67% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. ISIS: 2.70 )
ISIS' s 10-Year Price/Median PS Value Range
Min: 0.36   Max: 4.43
Current: 2.7

0.36
4.43
Earnings Yield (Greenblatt) -0.60
ISIS's Earnings Yield (Greenblatt) is ranked higher than
83% of the 1389 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. ISIS: -0.60 )
ISIS' s 10-Year Earnings Yield (Greenblatt) Range
Min: -0.6   Max: 0.3
Current: -0.6

-0.6
0.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ISI.Germany,
Isis Pharmaceuticals Inc was incorporated in California in 1989, and in January 1991 the Company changed its state of incorporation to Delaware. The Company is engaged in antisense drug discovery and development, exploiting a novel drug discovery platform it created to generate a pipeline of first-in-class drugs. Antisense technology provides a direct route from genomics to drugs. The Company business segments are Drug Discovery and Development operations. Its flagship product, KYNAMRO (mipomersen sodium) injection, is on the market in the United States for patients with homozygous familial hypercholesterolemia, or HoFH. Patients with HoFH are at high cardiovascular risk and cannot reduce their low-density lipoprotein cholesterol, or LDL-C, sufficiently with currently available lipid-lowering therapies. The Company has a pipeline of 31 drugs in development. Company's ISIS-TTR and ISIS-SMN drugs are in late stage development. Its partners include Biogen Idec, AstraZeneca and Roche. The Company's drugs compete with existing therapies for market share. It also competes with specialized pharmaceutical firms and large pharmaceutical companies acting either independently or together with biopharmaceutical companies. The Company is subject to regulation under the Occupational Safety and Health Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act and other present and potential future federal, state and local regulations.
» More Articles for ISIS

Headlines

Articles On GuruFocus.com
Analysts Provide Update for Biogen, PTC Therapeutics, GW Pharma, and Isis Pharma Apr 22 2015 
Value vs. Growth: Is Jim Cramer Right about ISIS Pharmaceuticals? Dec 13 2014 
Weekly CEO Sells Highlight: Keynote Systems Inc., Isis Pharmaceuticals, Coleman Cable Inc. Jul 01 2013 
Isis Pharmaceuticals Inc. (ISIS) Director, COO B Lynne Parshall sells 17,200 Shares Dec 29 2010 
Isis Pharmaceuticals Inc. (ISIS) Chairman, President, CEO Stanley T Crooke sells 32,000 Shares Dec 29 2010 
Isis Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 05 2010 
Isis Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2010 
Guru Stocks at 52-Week Low: The Dun & Bradstreet Corp, FTI Consulting Inc, Terra Nitrogen Company L. Mar 07 2010 
Guru Stocks at 52-Week Low: Dun & Bradstreet Corp, GameStop Corp, Dean Foods Company, SunPower Corp, Feb 21 2010 
Weekly Guru Bargains Highlights: Weatherford International, MetroPCS Communications, Isis Pharmaceut Feb 13 2010 


More From Other Websites
Isis Pharmaceuticals' ISIS-TTR Effective in Extension Study - Analyst Blog Apr 23 2015
Isis Pharmaceuticals Reports Positive Data From ISIS-TTR Rx in Patients With TTR Amyloidosis Apr 22 2015
Isis Pharmaceuticals Reports Positive Data From ISIS-TTR Rx in Patients With TTR Amyloidosis Apr 22 2015
CAR-T Therapy Stocks Hit Hard Following AACR Data Apr 20 2015
Biotech investors brace for updates on key drugs Apr 17 2015
Isis Pharmaceuticals to Present at Upcoming Investor Conferences Apr 10 2015
Isis Pharmaceuticals to Present at Upcoming Investor Conferences Apr 10 2015
5 biotech bets: Trading a surging sector Apr 09 2015
5 biotech bets: Large & small Apr 09 2015
Jim Cramer -- If You're Not in Biotech for the Long Haul, Hit the Road Apr 08 2015
Is Isis Pharmaceuticals (ISIS) Stock a Solid Choice Right Now? - Tale of the Tape Mar 31 2015
Retail Investors: Buyers in all Ten Sectors Last Week Mar 30 2015
Biotech “bubble” popped, time to buy again? Mar 27 2015
Lightning Round: It's the center of a blast zone Mar 25 2015
Cramer Remix: The selloff was made for this stock Mar 25 2015
Isis Pharmaceuticals Reports Phase I Data on Lipid Candidate - Analyst Blog Mar 24 2015
Isis Pharmaceuticals (ISIS) Stock Falls Today After Antisense Drug Trial Data Mar 23 2015
Isis Pharmaceuticals Reports Positive Phase 1 Data on Isis-ANGPTL3Rx Mar 23 2015
Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy Mar 23 2015
Isis Pharmaceuticals Reports Positive Phase 1 Data on Isis-ANGPTL3Rx Mar 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK